ArticleGland surgery2025
Predictive value of multiparametric magnetic resonance imaging combined with pathological biomarkers for axillary lymph node metastasis of breast cancer.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRI-Based Intratumoral and Multi-Range Peritumoral Radiomics for Predicting Axillary Lymph Node Metastasis in Breast Cancer.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Detection of metastases in axillary lymph nodes (ALNs) is of vital significance for determining appropriate therapeutic strategies and prognosis for breast cancer patients. Studies combining multiparametric magnetic resonance imaging (MRI) and pathological biomarkers for predicting ALN metastasis in breast cancer are rarely reported. This study aimed to evaluate the predictive value of conventional MRI features, intravoxel incoherent motion (IVIM), quantitative dynamic contrast-enhanced MRI (DCE-MRI), and pathological biomarkers for ALN metastasis in breast cancer patients. Methods: In total, 149 subjects with breast cancer confirmed via pathology were recruited for study. Among the participants, patients were randomly allocated to the training cohort (42 and 62 presented with ALN and non-ALN metastasis) or validation cohort (18 and 27 presented with ALN and non-ALN metastasis), respectively. All participants underwent both IVIM and DCE-MRI. The analysis focused on the clinicopathological characteristics along with conventional MRI features, in addition to assessment of a range of quantitative parameters, including DCE-MRI derived parameters (K Results: In the training and validation cohorts, patients with ALN metastasis had significantly higher Ki-67 (P=0.01, P=0.03) and hypoxia-inducible factor-1 alpha (HIF-1α) expression (P<0.001, P=0.04). Lymphovascular invasion (LVI) and programmed death ligand-1 (PD-L1) expression were significantly more common in the metastatic group (P=0.002, P=0.003, respectively) in the training cohort. In the training and test cohorts, compared to the non-metastatic group, patients with ALN metastasis exhibited significantly lower D values (all P<0.001) and significantly higher values of D* (P=0.02, P=0.04), K Conclusions: Combining MRI parameters (lesion margin, D, K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.